Küleon Bioscience
Küleon Bioscience discovers novel serotonergic drug candidates aimed at treating neuropsychiatric disorders such as schizophrenia and depression. The company uses proprietary, AI-based drug discovery technology and patentable molecular scaffolds to design functionally selective serotonin receptor ligands that exploit biased signaling. Its platform has produced multiple preclinical leads with improved agonism profiles, reduced hallucinogenic and cardiotoxic liability, and altered PK/PD versus existing atypical antipsychotics. Küleon operates as a drug discovery company partnering with academic researchers and industry collaborators to advance candidates toward clinical development. The target market includes large neuropsychiatric indication populations where selective serotonergic mechanisms may offer therapeutic advantages.
Küleon Bioscience
Küleon Bioscience discovers novel serotonergic drug candidates aimed at treating neuropsychiatric disorders such as schizophrenia and depression. The company uses proprietary, AI-based drug discovery technology and patentable molecular scaffolds to design functionally selective serotonin receptor ligands that exploit biased signaling. Its platform has produced multiple preclinical leads with improved agonism profiles, reduced hallucinogenic and cardiotoxic liability, and altered PK/PD versus existing atypical antipsychotics. Küleon operates as a drug discovery company partnering with academic researchers and industry collaborators to advance candidates toward clinical development. The target market includes large neuropsychiatric indication populations where selective serotonergic mechanisms may offer therapeutic advantages.